JP2005529116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529116A5 JP2005529116A5 JP2003585719A JP2003585719A JP2005529116A5 JP 2005529116 A5 JP2005529116 A5 JP 2005529116A5 JP 2003585719 A JP2003585719 A JP 2003585719A JP 2003585719 A JP2003585719 A JP 2003585719A JP 2005529116 A5 JP2005529116 A5 JP 2005529116A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- alkoxy
- group
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 10
- 206010020751 Hypersensitivity Diseases 0.000 claims 10
- 230000007815 allergy Effects 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 239000002464 receptor antagonist Substances 0.000 claims 10
- 229940044551 receptor antagonist Drugs 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 230000008369 airway response Effects 0.000 claims 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 7
- 208000027744 congestion Diseases 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 6
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 claims 6
- 229960001271 desloratadine Drugs 0.000 claims 6
- 229960003088 loratadine Drugs 0.000 claims 6
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 208000001953 Hypotension Diseases 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 230000009858 acid secretion Effects 0.000 claims 4
- 239000013566 allergen Substances 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000015114 central nervous system disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 230000036543 hypotension Effects 0.000 claims 4
- 206010027599 migraine Diseases 0.000 claims 4
- 230000004899 motility Effects 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- USCSJAIWXWYTEH-UHFFFAOYSA-N 7-[3-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one Chemical compound C1=CC=2C(C)=C(C)C(=O)OC=2C=C1OCCCN(CC1)CCN1CC1=CC=C(Cl)C=C1 USCSJAIWXWYTEH-UHFFFAOYSA-N 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 3
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims 3
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims 3
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 3
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 claims 3
- OGEAASSLWZDQBM-UHFFFAOYSA-N Temelastine Chemical compound C1=NC(C)=CC=C1CC(C(N1)=O)=CN=C1NCCCCC1=NC=C(Br)C=C1C OGEAASSLWZDQBM-UHFFFAOYSA-N 0.000 claims 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 3
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 3
- 229960003790 alimemazine Drugs 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 229960004574 azelastine Drugs 0.000 claims 3
- 229960000725 brompheniramine Drugs 0.000 claims 3
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 claims 3
- 229960000428 carbinoxamine Drugs 0.000 claims 3
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims 3
- 229960001803 cetirizine Drugs 0.000 claims 3
- 229960003291 chlorphenamine Drugs 0.000 claims 3
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 3
- 229960002881 clemastine Drugs 0.000 claims 3
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 3
- 229960001140 cyproheptadine Drugs 0.000 claims 3
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims 3
- 229960000520 diphenhydramine Drugs 0.000 claims 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 3
- 229960005178 doxylamine Drugs 0.000 claims 3
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 claims 3
- 229960001971 ebastine Drugs 0.000 claims 3
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 3
- 229960003592 fexofenadine Drugs 0.000 claims 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 3
- 229960000930 hydroxyzine Drugs 0.000 claims 3
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 3
- 229960004958 ketotifen Drugs 0.000 claims 3
- 229960001120 levocabastine Drugs 0.000 claims 3
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 3
- 229960001474 meclozine Drugs 0.000 claims 3
- 229960005042 mequitazine Drugs 0.000 claims 3
- 229960003955 mianserin Drugs 0.000 claims 3
- 229960001144 mizolastine Drugs 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229950010674 picumast Drugs 0.000 claims 3
- 229960003910 promethazine Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229950005829 temelastine Drugs 0.000 claims 3
- 229960000351 terfenadine Drugs 0.000 claims 3
- 229960003223 tripelennamine Drugs 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 239000000938 histamine H1 antagonist Substances 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000002009 allergenic effect Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000005306 thianaphthenyl group Chemical group 0.000 claims 1
- 229960001128 triprolidine Drugs 0.000 claims 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims 1
- 0 *c1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O Chemical compound *c1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O 0.000 description 4
- ORBVZPNZPGRGKS-UHFFFAOYSA-N C(CNCC1)C1[n]1c(nccc2)c2nc1-c1cc2ccccc2[nH]1 Chemical compound C(CNCC1)C1[n]1c(nccc2)c2nc1-c1cc2ccccc2[nH]1 ORBVZPNZPGRGKS-UHFFFAOYSA-N 0.000 description 1
- KMQWSMHYXYXNRT-UHFFFAOYSA-N COc1nc2cccnc2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O Chemical compound COc1nc2cccnc2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O KMQWSMHYXYXNRT-UHFFFAOYSA-N 0.000 description 1
- VKDJZOXMKLOALY-UHFFFAOYSA-N CSc([n]1C(CC2)CCN2C(C2(CCN(Cc3cnc(N)nc3)CC2)F)=O)nc2c1nccc2 Chemical compound CSc([n]1C(CC2)CCN2C(C2(CCN(Cc3cnc(N)nc3)CC2)F)=O)nc2c1nccc2 VKDJZOXMKLOALY-UHFFFAOYSA-N 0.000 description 1
- FNIQXFAXPBTTBF-UHFFFAOYSA-N CSc1nc(C=C(CC2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O Chemical compound CSc1nc(C=C(CC2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2cnc(N)nc2)CC1)=O FNIQXFAXPBTTBF-UHFFFAOYSA-N 0.000 description 1
- MSWZRRQDGCYMNN-UHFFFAOYSA-N CSc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O Chemical compound CSc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1(CCN(Cc2cnc(N)nc2)CC1)F)=O MSWZRRQDGCYMNN-UHFFFAOYSA-N 0.000 description 1
- GORJZHAQJFRYCJ-UHFFFAOYSA-N CSc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O Chemical compound CSc1nc(cc(cc2)F)c2[n]1C(CC1)CCN1C(C1CCN(Cc2ccnc(N)c2)CC1)=O GORJZHAQJFRYCJ-UHFFFAOYSA-N 0.000 description 1
- XFEOMNAEJJMTOX-UHFFFAOYSA-N Nc1ncc(CN(CC2)CCC2(C=O)F)cn1 Chemical compound Nc1ncc(CN(CC2)CCC2(C=O)F)cn1 XFEOMNAEJJMTOX-UHFFFAOYSA-N 0.000 description 1
- WMMXGSMJCAWWSF-UHFFFAOYSA-N Nc1ncc(CN(CC2)CCC2C=O)cn1 Chemical compound Nc1ncc(CN(CC2)CCC2C=O)cn1 WMMXGSMJCAWWSF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37373102P | 2002-04-18 | 2002-04-18 | |
| PCT/US2003/011672 WO2003088967A1 (en) | 2002-04-18 | 2003-04-16 | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005529116A JP2005529116A (ja) | 2005-09-29 |
| JP2005529116A5 true JP2005529116A5 (enExample) | 2006-12-21 |
| JP4384918B2 JP4384918B2 (ja) | 2009-12-16 |
Family
ID=29251069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585719A Expired - Lifetime JP4384918B2 (ja) | 2002-04-18 | 2003-04-16 | ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1499316B1 (enExample) |
| JP (1) | JP4384918B2 (enExample) |
| KR (1) | KR100827470B1 (enExample) |
| CN (1) | CN100522166C (enExample) |
| AR (1) | AR040405A1 (enExample) |
| AT (1) | ATE389406T1 (enExample) |
| AU (1) | AU2003223627B2 (enExample) |
| BR (1) | BR0309348A (enExample) |
| CA (1) | CA2481940A1 (enExample) |
| CY (1) | CY1110363T1 (enExample) |
| DE (1) | DE60319813T2 (enExample) |
| DK (1) | DK1499316T3 (enExample) |
| EC (1) | ECSP045367A (enExample) |
| ES (1) | ES2301791T3 (enExample) |
| IL (1) | IL164584A (enExample) |
| MX (1) | MXPA04010173A (enExample) |
| NO (1) | NO20045002L (enExample) |
| NZ (1) | NZ535763A (enExample) |
| PE (1) | PE20040684A1 (enExample) |
| PL (1) | PL373889A1 (enExample) |
| PT (1) | PT1499316E (enExample) |
| RU (1) | RU2323935C2 (enExample) |
| SI (1) | SI1499316T1 (enExample) |
| TW (1) | TW200306183A (enExample) |
| WO (1) | WO2003088967A1 (enExample) |
| ZA (1) | ZA200407984B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050100615A (ko) | 2003-01-14 | 2005-10-19 | 싸이토키네틱스, 인코포레이티드 | 화합물, 조성물 및 방법 |
| AU2004238447C1 (en) | 2003-04-23 | 2009-06-11 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| CA2570999C (en) | 2004-06-17 | 2014-01-07 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| WO2006038738A1 (ja) * | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| CA2595157A1 (en) | 2005-01-21 | 2006-07-27 | Schering Corporation | Imidazole and benzimidazole derivatives useful as histamine h3 antagonists |
| EP1902046B1 (en) | 2005-06-20 | 2009-12-02 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
| US7408066B2 (en) | 2005-06-20 | 2008-08-05 | Schering Corproation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| CA2623025A1 (en) | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| CN101273026A (zh) | 2005-09-30 | 2008-09-24 | 霍夫曼-拉罗奇有限公司 | 作为mch受体拮抗剂的茚满衍生物 |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| JP2009521448A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| CA2634235A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| KR20080085031A (ko) * | 2006-01-13 | 2008-09-22 | 에프. 호프만-라 로슈 아게 | 사이클로헥실 피페라지닐 메탄온 유도체 및 히스타민 ｈ3수용체 조절제로서의 이의 용도 |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| CA2691782A1 (en) * | 2007-09-11 | 2009-03-19 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| WO2011082270A2 (en) | 2009-12-30 | 2011-07-07 | Arqule. Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| WO2012177852A1 (en) | 2011-06-24 | 2012-12-27 | Arqule, Inc | Substituted imidazopyridinyl compounds |
| WO2012177844A2 (en) | 2011-06-24 | 2012-12-27 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| KR101127756B1 (ko) | 2011-09-02 | 2012-03-23 | 한국과학기술원 | Ｇｉｔ１ 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP6046646B2 (ja) | 2014-01-10 | 2016-12-21 | 信越化学工業株式会社 | オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法 |
| US10595550B2 (en) * | 2014-01-22 | 2020-03-24 | Vision Pharma, Llc | Therapeutic composition including carbonated solution |
| US10118900B2 (en) | 2015-08-25 | 2018-11-06 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as CB-1 inverse agonists |
| US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD290192A5 (de) * | 1986-11-13 | 1991-05-23 | Eisai Co. Ltd,Jp | Pyridinderivat mit antiulzeroeser wirkung |
| ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| DE69415391T2 (de) * | 1993-05-26 | 1999-08-26 | Sumitomo Pharmaceuticals Co. | Chinazolinonderivate |
| US6211199B1 (en) * | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| KR19990087131A (ko) * | 1996-02-21 | 1999-12-15 | 게리 디. 스트리트, 스티븐 엘. 네스비트 | 알레르기 질환의 치료에 유용한 신규한 치환된 n-메틸-n-(4-(4-(1h-벤즈이미다졸-2-일-아미노)피페리딘-1-일)-2-(아릴)부틸)벤즈아미드 |
| WO1998050368A1 (en) * | 1997-05-01 | 1998-11-12 | Nissan Chemical Industries, Ltd. | Benzimidazole derivative |
| US6133291A (en) * | 1998-10-16 | 2000-10-17 | Schering Corporation | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists |
| HK1052179A1 (zh) * | 2000-09-20 | 2003-09-05 | Schering Corporation | 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑 |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| NZ535764A (en) * | 2002-04-18 | 2007-10-26 | Schering Corp | 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists |
-
2003
- 2003-04-16 WO PCT/US2003/011672 patent/WO2003088967A1/en not_active Ceased
- 2003-04-16 SI SI200331201T patent/SI1499316T1/sl unknown
- 2003-04-16 DE DE60319813T patent/DE60319813T2/de not_active Expired - Lifetime
- 2003-04-16 AT AT03719766T patent/ATE389406T1/de not_active IP Right Cessation
- 2003-04-16 NZ NZ535763A patent/NZ535763A/en not_active IP Right Cessation
- 2003-04-16 BR BR0309348-4A patent/BR0309348A/pt not_active IP Right Cessation
- 2003-04-16 MX MXPA04010173A patent/MXPA04010173A/es active IP Right Grant
- 2003-04-16 PL PL03373889A patent/PL373889A1/xx not_active Application Discontinuation
- 2003-04-16 ES ES03719766T patent/ES2301791T3/es not_active Expired - Lifetime
- 2003-04-16 AR AR20030101340A patent/AR040405A1/es active IP Right Grant
- 2003-04-16 CA CA002481940A patent/CA2481940A1/en not_active Abandoned
- 2003-04-16 EP EP03719766A patent/EP1499316B1/en not_active Expired - Lifetime
- 2003-04-16 PE PE2003000390A patent/PE20040684A1/es not_active Application Discontinuation
- 2003-04-16 DK DK03719766T patent/DK1499316T3/da active
- 2003-04-16 CN CNB038137798A patent/CN100522166C/zh not_active Expired - Fee Related
- 2003-04-16 JP JP2003585719A patent/JP4384918B2/ja not_active Expired - Lifetime
- 2003-04-16 KR KR1020047016508A patent/KR100827470B1/ko not_active Expired - Fee Related
- 2003-04-16 PT PT03719766T patent/PT1499316E/pt unknown
- 2003-04-16 RU RU2004133764/04A patent/RU2323935C2/ru not_active IP Right Cessation
- 2003-04-16 AU AU2003223627A patent/AU2003223627B2/en not_active Ceased
- 2003-04-17 TW TW092108912A patent/TW200306183A/zh unknown
-
2004
- 2004-10-04 ZA ZA200407984A patent/ZA200407984B/xx unknown
- 2004-10-14 IL IL164584A patent/IL164584A/en not_active IP Right Cessation
- 2004-10-15 EC EC2004005367A patent/ECSP045367A/es unknown
- 2004-11-17 NO NO20045002A patent/NO20045002L/no unknown
-
2008
- 2008-06-09 CY CY20081100604T patent/CY1110363T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005529116A5 (enExample) | ||
| RU2003114748A (ru) | Новые соединения, не являющиеся имидазолами | |
| RU2004133764A (ru) | Производные бензимидазола в качестве н3-гистаминовых антагонистов | |
| US6426347B2 (en) | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | |
| RU2007104096A (ru) | Способ лечения аллергии или вызываемых аллергией поражений дыхательных путей и фармацевтическая композиция | |
| JP2013513613A5 (enExample) | ||
| RU2009125019A (ru) | Производные карбоновой кислоты | |
| BR0017025A (pt) | Antagonistas do receptor y5 do neuropeptìdeo y de imidazola substituìda | |
| KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
| BR0010607A (pt) | Derivados de piperidina úteis como antagonistas de ccr5 | |
| RU2008146088A (ru) | Оксадиазолидиндионовое соединение | |
| RU2008144663A (ru) | Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких | |
| JP2010508296A5 (enExample) | ||
| HRP20050432A2 (en) | Novel medicaments for the treatment of chronic obstructive pulmonary diseases | |
| MXPA06001838A (es) | Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento. | |
| JP2008513515A5 (enExample) | ||
| CA2489337A1 (en) | Indole derivatives useful as histamine h3 antagonists | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| CN100430383C (zh) | 可用于治疗性功能障碍的苯并咪唑 | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| BRPI0519398A2 (pt) | compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| MY135821A (en) | Therapeutic agents | |
| NO20084674L (no) | 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser | |
| Kakefuda et al. | Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1, 2, 4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V1a receptor |